Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAM-531 in Mild to Moderate Alzheimer's Disease
NCT00895895Phase 2Terminated
- Sponsor
- Pfizer
- Start
- May 2009
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 2 trial of cerlapirdine in Alzheimer's disease (AD), sponsored by Pfizer. Started May 2009; status: terminated.
02
Drugs
cerlapirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00895895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00895895.